Cargando…

Combined Dexamethasone Intravitreal Implant and Glaucoma Drainage Device Placement for Uveitic Glaucoma

PRECIS: At 1-year postoperative follow-up, concurrent placement of a dexamethasone intravitreal implant and glaucoma drainage device effectively controlled intraocular pressure (IOP) and inflammation in eyes with uveitic glaucoma with no changes in systemic immunomodulatory therapy. PURPOSE: The pur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Tran, Kim, Han, Mielke, Christy, Momont, Anna C., Brandt, James D., Liu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health, Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147398/
https://www.ncbi.nlm.nih.gov/pubmed/31990825
http://dx.doi.org/10.1097/IJG.0000000000001454
_version_ 1783520412681895936
author Nguyen, Tran
Kim, Han
Mielke, Christy
Momont, Anna C.
Brandt, James D.
Liu, Yao
author_facet Nguyen, Tran
Kim, Han
Mielke, Christy
Momont, Anna C.
Brandt, James D.
Liu, Yao
author_sort Nguyen, Tran
collection PubMed
description PRECIS: At 1-year postoperative follow-up, concurrent placement of a dexamethasone intravitreal implant and glaucoma drainage device effectively controlled intraocular pressure (IOP) and inflammation in eyes with uveitic glaucoma with no changes in systemic immunomodulatory therapy. PURPOSE: The purpose of this study was to assess 1-year postoperative outcomes in eyes with uncontrolled uveitic glaucoma following concurrent placement of a dexamethasone intravitreal implant and glaucoma drainage device. MATERIALS AND METHODS: This is a retrospective, observational case series of patients with chronic, noninfectious uveitis and uveitic glaucoma uncontrolled on maximal tolerated medical therapy with at least 1-year postoperative follow-up. The main outcomes were visual acuity, IOP, number of glaucoma medications, recurrent inflammation, frequency of topical steroids, systemic immunomodulatory therapy, and adverse events. Success was defined as IOP <21 mm Hg and IOP reduced by >20% from baseline on at least 2 consecutive visits after 3 months either with or without glaucoma medications (ie, partial or complete success, respectively). RESULTS: Eight eyes in 6 patients met the inclusion criteria. The average age was 44.1±19.7 years (range: 10 to 68 y) and 50% were female. At 1-year, there was no significant change in visual acuity. No eyes lost ≥3 lines of vision. The majority of eyes (87.5%) achieved complete (n=2) or partial success (n=5) with a decrease in average IOP from 36.5 to 11.8 mm Hg (P=0.002). Glaucoma medication use decreased from 3.0 to 1.3 medications (P=0.04). There was a significant decrease in the number of episodes of recurrent inflammation in the 6 months following surgery compared with the 6 months before surgery (P=0.004). CONCLUSION: In this small case series, dexamethasone intravitreal implant combined with Ahmed glaucoma drainage device appears to be an effective approach for the management of uncontrolled uveitic glaucoma.
format Online
Article
Text
id pubmed-7147398
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health, Inc
record_format MEDLINE/PubMed
spelling pubmed-71473982020-04-24 Combined Dexamethasone Intravitreal Implant and Glaucoma Drainage Device Placement for Uveitic Glaucoma Nguyen, Tran Kim, Han Mielke, Christy Momont, Anna C. Brandt, James D. Liu, Yao J Glaucoma Original Studies PRECIS: At 1-year postoperative follow-up, concurrent placement of a dexamethasone intravitreal implant and glaucoma drainage device effectively controlled intraocular pressure (IOP) and inflammation in eyes with uveitic glaucoma with no changes in systemic immunomodulatory therapy. PURPOSE: The purpose of this study was to assess 1-year postoperative outcomes in eyes with uncontrolled uveitic glaucoma following concurrent placement of a dexamethasone intravitreal implant and glaucoma drainage device. MATERIALS AND METHODS: This is a retrospective, observational case series of patients with chronic, noninfectious uveitis and uveitic glaucoma uncontrolled on maximal tolerated medical therapy with at least 1-year postoperative follow-up. The main outcomes were visual acuity, IOP, number of glaucoma medications, recurrent inflammation, frequency of topical steroids, systemic immunomodulatory therapy, and adverse events. Success was defined as IOP <21 mm Hg and IOP reduced by >20% from baseline on at least 2 consecutive visits after 3 months either with or without glaucoma medications (ie, partial or complete success, respectively). RESULTS: Eight eyes in 6 patients met the inclusion criteria. The average age was 44.1±19.7 years (range: 10 to 68 y) and 50% were female. At 1-year, there was no significant change in visual acuity. No eyes lost ≥3 lines of vision. The majority of eyes (87.5%) achieved complete (n=2) or partial success (n=5) with a decrease in average IOP from 36.5 to 11.8 mm Hg (P=0.002). Glaucoma medication use decreased from 3.0 to 1.3 medications (P=0.04). There was a significant decrease in the number of episodes of recurrent inflammation in the 6 months following surgery compared with the 6 months before surgery (P=0.004). CONCLUSION: In this small case series, dexamethasone intravitreal implant combined with Ahmed glaucoma drainage device appears to be an effective approach for the management of uncontrolled uveitic glaucoma. Wolters Kluwer Health, Inc 2020-04 2020-01-23 /pmc/articles/PMC7147398/ /pubmed/31990825 http://dx.doi.org/10.1097/IJG.0000000000001454 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Studies
Nguyen, Tran
Kim, Han
Mielke, Christy
Momont, Anna C.
Brandt, James D.
Liu, Yao
Combined Dexamethasone Intravitreal Implant and Glaucoma Drainage Device Placement for Uveitic Glaucoma
title Combined Dexamethasone Intravitreal Implant and Glaucoma Drainage Device Placement for Uveitic Glaucoma
title_full Combined Dexamethasone Intravitreal Implant and Glaucoma Drainage Device Placement for Uveitic Glaucoma
title_fullStr Combined Dexamethasone Intravitreal Implant and Glaucoma Drainage Device Placement for Uveitic Glaucoma
title_full_unstemmed Combined Dexamethasone Intravitreal Implant and Glaucoma Drainage Device Placement for Uveitic Glaucoma
title_short Combined Dexamethasone Intravitreal Implant and Glaucoma Drainage Device Placement for Uveitic Glaucoma
title_sort combined dexamethasone intravitreal implant and glaucoma drainage device placement for uveitic glaucoma
topic Original Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147398/
https://www.ncbi.nlm.nih.gov/pubmed/31990825
http://dx.doi.org/10.1097/IJG.0000000000001454
work_keys_str_mv AT nguyentran combineddexamethasoneintravitrealimplantandglaucomadrainagedeviceplacementforuveiticglaucoma
AT kimhan combineddexamethasoneintravitrealimplantandglaucomadrainagedeviceplacementforuveiticglaucoma
AT mielkechristy combineddexamethasoneintravitrealimplantandglaucomadrainagedeviceplacementforuveiticglaucoma
AT momontannac combineddexamethasoneintravitrealimplantandglaucomadrainagedeviceplacementforuveiticglaucoma
AT brandtjamesd combineddexamethasoneintravitrealimplantandglaucomadrainagedeviceplacementforuveiticglaucoma
AT liuyao combineddexamethasoneintravitrealimplantandglaucomadrainagedeviceplacementforuveiticglaucoma